Gastredner
Ranjana H. Advani Ranjana H. Advani is Associate Professor of Medicine in the Division of Oncology at the Stanford University School of Medicine in Stanford, California (since 2011). She received her undergraduate and medical degree from Bombay University, India, and finished her residency in 1986 at Santa Clara Valley Medical Center in San José, California. Following residency, Dr. Advani completed both Hematology and Oncology fellowship programs at Stanford University. Dr. Advani is a Diplomate of the American Board of Internal Medicine and the American Board of Medical Specialties (Hematology and Oncology). She is a member of the Stanford General Clinical Research Center (GCRC) Advisory Board and serves on the Lymphoma Core Committee of the Eastern Cooperative Oncology Group as well as the Guidelines Committee (Hodgkin’s Disease and Non-Hodgkin’s Lymphoma) of the National Comprehensive Cancer Network (NCCN, since 2004). Her research interest is mainly translational and relates to clinical investigation of Hodgkin’s disease, Non-Hodgkin’s lymphomas and Cutaneous lymphomas. She is currently the Co-Director of the Oncology Fellow Program. |
Michael Boutros Michael Boutros is heading the Division of Signaling and Functional Genomics and is the Coordinator of the Functional and Structural Genomics Program at the German Cancer Research Center (DKFZ). He is also full Professor for Cell and Molecular Biology at Heidelberg University. After his PhD at the European Molecular Biology Laboratory (EMBL), he joined Harvard Medical School in Boston as a postdoctoral fellow in the Department of Genetics. In 2003, he started his independent group at the DKFZ supported by an Emmy-Noether Grant of the German Research Foundation (DFG) and by the EMBO Young Investigator Program. His lab works on functional genomic approaches to understand the regulation of cellular signaling during homeostasis and in cancer. A particular focus lies on the dissection of Wnt signaling pathways and their Dysregulation in cancer. His research has been supported by an Advanced Grant of the European Research Council (ERC), he is the Coordinating PI of a recently awarded ERC Synergy Grant and the Vice-Speaker of the DFG-funded Collaborative Research Center SFB1324 on Wnt Signaling. He received fellowships from the Studienstiftung des deutschen Volkes, the Boehringer Ingelheim Foundation and the Fulbright Commission. Michael Boutros is an elected member of the European Molecular Biology Organisation (EMBO). |
Stefan Hell Stefan Hell is the director at the Max Planck Institute for Biophysical Chemistry in Göttingen as well as at the Max Planck Institute for Medical Research in Heidelberg. Hell is credited with having conceived, validated and applied the first viable concept for overcoming Abbe’s diffraction-limited resolution barrier in a light-focusing fluorescence microscope. For this accomplishment he has received numerous awards, including the 2014 Kavli Prize in Nanoscience and the Nobel Prize in Chemistry. Stefan Hell received his doctorate (1990) in physics from the University of Heidelberg. From 1991 to 1993 he worked at the European Molecular Biology Laboratory, followed by stays as a senior researcher at the University of Turku, Finland, between 1993 and 1996, and as a visiting scientist at the University of Oxford, England, in 1994. In 1997 he was appointed to the MPI for Biophysical Chemistry in Göttingen as a group leader, and was promoted to director in 2002. From 2003 to 2017 he also led a research group at the German Cancer Research Center (DKFZ). Hell holds honorary professorships in physics at the Universities of Heidelberg and Göttingen. |
Heyo K. Kroemer Heyo K. Kroemer is the Chairman of the Board of the Charité – Universitätsmedizin Berlin since September 2019. His Research topics are drug metabolism and transport. In 1983 Kroemer received his Diploma in Pharmacy and in 1986 his Doctor in Pharmacology from University Braunschweig. In 1998 he was appointed to the University of Bonn as Professor for Clinical Pharmacy. From 1998 to 2012 he was Professor for Pharmacology and Toxicology at University of Greifswald, and later was promoted to Dean of the Medical School (2000–2012). He is a member of the Scientific Advisory Board of the Federal Pharmacy Chamber since 2006, since 2007 he is a member of the Executive Committee of the German Medical Faculty Association (MFT), later Vice-President (since 2009) and President (since 2012). He is currently member of the Senate Committee on Collaborative Research Centres of the DFG. |
Tak W. Mak Samstag, 12.10.2019, 14:00–14:30 Ebene 3/M4/M5 Tak W. Mak is internationally known for his work in the molecular biology of cancer and the immune system. He is a Professor in the Department of Medical Biophysics and the Department of Immunology at the University of Toronto; the Director of the Campbell Family Institute for Breast Cancer Research at the Princess Margaret Cancer Centre; Senior Scientist at the Ontario Cancer Institute and Professor, University of Hong Kong. Dr. Mak is a world leader in the genetics of immunology and cancer. In 1984, he led the group that discovered the T cell receptor, and his published work on the cloning of T cell antigen receptor genes has been cited over 1,400 times. Since this landmark discovery, Dr. Mak has focused on elucidating the mechanisms underlying immune responses and tumorigenesis. He pioneered the use of genetically engineered mouse strains to identify genetic susceptibility factors associated with various immune disorders or different types of cancer. In particular, his team discovered that CTLA4 is a negative regulator of T cell activation (cited 3,000 times), paving the way for the development of anti-CTLA4 agents now in clinical use for autoimmune diseases. Dr. Mak’s lab also made major contributions to defining the functions of PTEN (cited >3,000 times) as well as the relationship between the breast cancer susceptibility genes BRCA1 and BRCA2 and defects in DNA repair. Most recently, Dr. Mak’s studies of the functions of various gene products in normal and cancerous cells are yielding important Information on their biology that is crucial for the identification of new drug targets and the development of more effective cancer therapies. |